Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited (NASDAQ: APM) is described in its public communications as a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology, including orphan oncology indications, and infectious diseases. The company’s news flow also reflects its involvement in healthcare services and diagnostics collaborations, such as the co-development of the PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology.
Recent Aptorum news has highlighted a series of significant corporate and strategic developments. A central theme is the proposed all-stock merger with DiamiR Biosciences Corp., a molecular diagnostics company focused on minimally invasive tests for brain health and other diseases. Multiple joint press releases describe the Agreement and Plan of Merger, the expected ownership split between Aptorum shareholders and DiamiR stockholders, and the intention for DiamiR to become a wholly owned subsidiary of Aptorum, subject to shareholder approvals and customary closing conditions.
News items also cover DiamiR’s activities that are relevant to the combined story, including acceptance of scientific abstracts at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and regulatory milestones such as New York State approval for DiamiR’s APOE genotyping test. These updates emphasize DiamiR’s CLIA-certified, CAP-accredited laboratory, its microRNA-based platform for brain-enriched and inflammation-associated biomarkers, and its focus on brain health and neurodegenerative diseases.
In addition, Aptorum’s news releases describe financing transactions, including registered direct offerings of Class A ordinary shares and concurrent private placements of warrants, with stated uses of proceeds that include funding expenses related to the proposed merger and general working capital. Other announcements address Nasdaq listing matters, such as receipt of a minimum bid price deficiency notice and subsequent regaining of compliance with Nasdaq’s minimum bid price requirement.
Investors and observers following APM news can therefore expect updates on the progress of the proposed merger with DiamiR, scientific and regulatory developments connected to DiamiR’s diagnostics portfolio, Aptorum’s financing activities, and disclosures related to its Nasdaq listing status and SEC filings. The news stream collectively provides insight into how Aptorum presents its evolving strategy across oncology, infectious diseases, and, through the planned merger, brain health-focused diagnostics.
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced publication of a study titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics on March 10, 2026. The peer-reviewed study, conducted with the University of Pennsylvania, shows feasibility of detecting glioblastoma via a minimally invasive blood plasma microRNA test, identifying specific microRNA signatures with potential diagnostic and monitoring utility versus invasive biopsies or costly imaging.
Aptorum Group (NASDAQ: APM) announced receipt of a Nasdaq notification dated March 5, 2026, for non-compliance with the $1 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The notification does not affect current trading. Aptorum has a 180-calendar-day cure period until September 1, 2026, to regain compliance and is evaluating options, including a possible reverse stock split, to restore compliance.
Aptorum Group (NASDAQ: APM) announced a collaboration between DiamiR Biosciences and Instant NanoBiosensors to validate INB’s automated G8 Genotyping Analyzer for APOE testing in DiamiR’s CLIA-certified, CAP-accredited laboratory.
The project will compare INB’s platform to DiamiR’s New York State approved APOE test to evaluate analytical performance, clinical suitability, and potential to increase testing throughput. Financial terms were not disclosed.
DiamiR Biosciences and Aptorum Group (NASDAQ: APM) announced two poster presentations accepted for the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Dec 1–4, 2025 in San Diego and online. The posters focus on brain-enriched and inflammation-associated microRNAs as plasma epigenetic biomarkers to classify cognitively unimpaired, MCI, and AD participants and to characterize stages of neurodegeneration.
Presentations occur in the Clinical Trials: Biomarkers session on Dec 3, 2025 (7:15 AM–5:30 PM PST) at the Hilton San Diego Bayfront; poster #225 was conducted with NYU ADRC (grant P30AG066512) and poster #240 with UPenn ADRC. Studies were funded by NIA SBIR grant R44AG044860.
Aptorum Group (NASDAQ: APM) priced a registered direct offering of 1,000,000 Class A ordinary shares at $2.00 per share for expected gross proceeds of $2.0 million, with a concurrent private placement of unregistered warrants to buy up to 2,000,000 shares at $2.00 per share. Closing is expected on or about October 14, 2025, subject to customary conditions.
The warrants are exercisable upon issuance, expire 24 months after effectiveness of a resale registration statement, and could provide up to $4.0 million additional gross proceeds if fully exercised. Net proceeds are intended to fund expenses tied to the planned merger with DiamiR Biosciences and general working capital; the merger remains subject to contingencies including shareholder approval.
Aptorum Group (NASDAQ: APM) announced board and management changes tied to its planned all-stock merger with DiamiR Biosciences, expected to close in Q4 2025. Upon closing, DiamiR will become a wholly owned subsidiary and Aptorum will add Dr. Laura A. Philips as an independent director. DiamiR co-founder Dr. Kira Sheinerman will join the combined board as a director, and DiamiR CEO Dr. Alidad Mireskandari will join as President and Chief Operating Officer and take a board observer seat. The announcement highlights added expertise in molecular diagnostics, Alzheimer’s early-detection tests, and commercialization experience for the combined company.
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced their joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 10, 2025, at 11 AM ET. The presentation will be delivered by DiamiR's CEO, Dr. Alidad Mireskandari, at the Lotte New York Palace Hotel in New York.
This presentation follows the companies' previously announced all-stock merger agreement from July 16, 2025, where DiamiR will become a wholly-owned subsidiary of Aptorum Group. The merger transaction is pending stockholder approval from both companies and is expected to close in Q4 2025.
DiamiR Biosciences and Aptorum Group (NASDAQ: APM) have announced that DiamiR has received Clinical Laboratory Evaluation Program (CLEP) Test Approval from the New York State Department of Health for its APOE Genotyping test.
This regulatory milestone enables DiamiR to provide validated APOE Genotyping molecular testing through its CLIA-certified and CAP-accredited clinical laboratory. The test can analyze various biological samples including blood, buccal swab, saliva, and tissue, and will be available to licensed healthcare providers in New York State and nationwide.
The approval expands access to a diagnostic tool for brain health assessment, particularly for neurodegenerative conditions like mild cognitive impairment and Alzheimer's disease.
Aptorum Group (NASDAQ: APM) has successfully regained compliance with Nasdaq's minimum bid price requirement, following its Class A ordinary shares maintaining a closing bid price of at least $1.00 for 10 consecutive business days from July 16 to July 30, 2025. This achievement comes before the October 14, 2025 deadline set by Nasdaq.
Additionally, the company announced on July 14, 2025, that it has entered into a definitive agreement for an all-stock merger with DiamiR Biosciences, a developer of blood-based tests for brain health and other diseases. Upon completion of the merger, DiamiR Biosciences, which operates a CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT, will become a wholly-owned subsidiary of Aptorum Group.
Aptorum Group (NASDAQ: APM) has announced a definitive agreement for an all-stock merger with DiamiR Biosciences, a developer of blood-based tests for brain health and other diseases. Upon merger completion, DiamiR will become a wholly-owned subsidiary of Aptorum while maintaining its name.
The combined entity will remain listed on the Nasdaq Stock Market, aiming to leverage DiamiR's CLIA-licensed, CAP-accredited clinical laboratory in New Haven, CT. The merger strategically combines Aptorum's biopharmaceutical capabilities with DiamiR's expertise in blood-based testing, particularly focusing on brain health, neurodegenerative diseases, oncology, and autoimmune indications.
The combined company aims to generate revenue through biopharma services and biomarker panels for complex-biology indications.